PolyNovo (PNV) Stock Price, News & Analysis

Company Overview

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3.38 million shs
• Average Volume: N/A
• Market Capitalization: A$1.30 billion
• P/E Ratio: 247.31
• Dividend Yield: 6.86%
• Price Target: N/A
• Consensus Rating: N/A

PNV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of PolyNovo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PolyNovo investors own include Align Technology (ALGN), Amgen (AMGN), Docusign (DOCU), Panoramic Resources (PAN), Plug Power (PLUG) and Roku (ROKU).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:PNV
• CIK: N/A
• Web: www.polynovo.com.au
• Phone: 61 3 8681 4050
• Fax: N/A
• Employees: 237
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A$0.01
• Trailing P/E Ratio: 247.31
• Forward P/E Ratio: N/A
• P/E Growth: 2.63
• Net Income: A$5.26 million
• Net Margins: 5.10%
• Pretax Margin: N/A
• Return on Equity: 7.45%
• Return on Assets: 0.56%

Debt

• Debt-to-Equity Ratio: 21.32
• Current Ratio: 3.41
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: A$103.23 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 207.50
• Book Value: A$0.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 690,760,000
• Free Float: N/A
• Market Cap: A$1.30 billion
• Optionable: Not Optionable
• Beta: 1.67